Cosmos Health (NASDAQ:COSM) will launch Cur18 in the U.S. in Q2 2026, a patented, turmeric‑derived curcumin supplement standardized to ~50% curcuminoids and derived ~98.5% from turmeric.
Published pharmacokinetic research reports up to 39× higher free curcumin bioavailability and 49.5× higher AUC versus standard 95% extracts.
Loading…
Loading translation…
Positive
39× higher free curcumin bioavailability (published PK research)
49.5× higher total curcumin AUC versus C-95 reference
Patented formulation with self-affirmed GRAS ingredient status
Randomized RCT (n=101) showed improved knee pain and function
Planned Q2 2026 U.S. multi-channel market launch
Negative
Pharmacokinetic study sample size was 18 subjects
Curcuminoid standardization at ~50% versus typical 95% extracts
-5.24%
Since News
$0.39
Last Price
$0.37
$0.45
Day Range
-$1M
Valuation Impact
$20.61M
Market Cap
0.0x
Rel. Volume
Following this news, COSM has declined 5.24%, reflecting a notable negative market reaction.
Our momentum scanner has triggered 10 alerts so far, indicating notable trading interest and price volatility.
The stock is currently trading at $0.39.
This price movement has removed approximately $1M from the company’s valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Free curcumin bioavailability
up to 39× higher
Versus standard 95% curcuminoid extracts in PK research
Total curcumin exposure (AUC)
49.5× higher
Versus C-95 reference in PK study
Turmeric-derived content
~98.5%
Portion of formulation derived from turmeric
Curcuminoid content
~50%
Standardized curcuminoids in Cur18
extract
PK study size
18 subjects
Randomized, double-blind crossover PK study in healthy adults
OA trial size
101 subjects
Randomized, double-blind, placebo-controlled osteoarthritis study
LD50
> 5,000 mg/kg
Repeat-dose safety data for Cur18 ingredient
Global turmeric market 2035
$8.4 billion
Projected global turmeric market size by 2035
$0.4060
Last Close
Volume
Volume 3,338,276 is 2.78× the 20-day average of 1,199,108, indicating elevated interest pre-announcement.
high
Technical
Shares at $0.406 are trading below the 200-day MA of $0.63 and 69.24% under the 52-week high.
COSM is up 3.97% with high volume, while key peers show mixed moves: SNYR -4.9%, ZYXI -37.34%, YI -3.33%, EDAP +1.41%, QIPT 0%. Momentum scanner only flags VVOS at -10.54%, reinforcing a stock-specific reaction.
Date
Event
Sentiment
Move
Catalyst
Apr 13
Purchase order win
Positive
+8.5%
Repeat Pharmalink order lifting Sky Premium Life volumes toward 3M‑unit goal.
Apr 10
Conflict impact update
Positive
+3.5%
No conflict impact and strong Q3 2025 growth with NOOR U.S. rollout plans.
Apr 08
New product launch
Positive
+0.6%
Announcement of Liv18 U.S. launch targeting large liver supplements market.
Apr 01
Clinical performance data
Positive
+0.6%
C-Scrub Wash 4% meeting EN 12791 standard for surgical hand disinfection.
Mar 19
Corporate update
Positive
-0.4%
Update on record growth, U.S. expansion and high-margin projections with guidance plans.
Pattern Detected
For similar ‘crypto’‑tagged updates, COSM most often trades higher on news, with 4 of 5 prior events showing positive next‑day moves and only one mild divergence.
Recent Company History
Over recent months, Cosmos Health has repeatedly highlighted U.S. and international expansion, new product launches, and strong operating trends. Prior crypto‑tagged releases covered hospital market entry with C‑Scrub Wash 4%, expansion of Sky Premium Life in the UAE toward a 3 million‑unit goal, U.S. NOOR collagen revenue projected above $12M, and record growth with expected ~75% gross margins. Today’s Cur18 U.S. launch fits this pattern of nutraceutical growth and geographic expansion.
+2.5%
Average Historical Move
crypto
Past crypto-tagged updates moved COSM an average of 2.54%, mostly on expansion and high-margin growth themes, similar to today’s U.S. Cur18 nutraceutical launch.
Crypto-tagged releases show a progression from capacity and margin updates to multiple U.S. product launches and broader international distribution initiatives.
$200,000,000
registered capacity
Cosmos Health has an effective Form S-3 shelf filed on 2025-11-07, registering up to $200,000,000 of securities and including an ATM program of up to $100,000,000 in common stock, primarily for crypto asset acquisitions and general purposes. As of the latest data, usage_count is 0.
The stock is down -5.2% following this news. A negative reaction despite product-launch news would fit a divergence scenario occasionally seen in COSM’s history, where one of five comparable crypto-tagged events moved against positive fundamentals. Pressure from its shelf registration of up to $200M, or concerns about execution in a competitive U.S. nutraceutical market, could weigh on sentiment even when operational updates appear constructive.
bioavailability
medical
“Cur18 enters the U.S. curcumin category… addressing… poor bioavailability.”
Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company’s success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.
pharmacokinetic
medical
“Based on published pharmacokinetic research, the formulation technology behind Cur18…”
Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.
randomized, double-blind
medical
“A randomized, double-blind crossover pharmacokinetic study in 18 healthy adult male subjects…”
A randomized, double-blind study is a clinical trial design where participants are assigned by chance to different groups (for example, a new treatment or a control) and neither the participants nor the researchers know who is in which group. This setup reduces conscious or unconscious bias—think of it like a blind taste test—so results are more reliable and investors can have greater confidence that reported effects reflect the treatment itself rather than expectations or selective reporting.
placebo-controlled
medical
“A randomized, double-blind, placebo-controlled osteoarthritis study in 101 subjects…”
“Placebo-controlled” describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
AUC
medical
“The same study reported 49.5× higher total curcumin AUC, along with a dual-phase…”
Area under the curve (AUC) measures the total exposure of the body to a drug over time by calculating the area beneath a plot of drug concentration versus time. For investors, AUC indicates how much of a medicine reaches and stays in the bloodstream, which affects dosing, safety and effectiveness—similar to measuring how much water flows through a pipe over a day rather than just its peak pressure.
GRAS
regulatory
“The ingredient has been described as self-affirmed GRAS (Generally Recognized as Safe)…”
GRAS stands for “Generally Recognized As Safe,” a U.S. regulatory designation for food ingredients or additives judged safe for their intended use based on scientific evidence or widespread expert consensus. For investors, GRAS status is like a safety stamp or building permit: it reduces regulatory hurdles, shortens time to market and lowers the risk of costly delays or product recalls, which can directly affect a company’s revenue and valuation.
LD50
medical
“Additional data include LD50 > 5,000 mg/kg and a 90-day repeat-dose safety study…”
LD50 (lethal dose 50%) is a standard toxicology measure that estimates the amount of a substance, usually given per unit of body weight, expected to kill half of a test population in controlled studies. For investors, LD50 gives a simple way to compare how dangerous a chemical or drug may be, signaling potential safety problems, regulatory hurdles, liability risks, and whether extra testing or protective measures could affect development costs and marketability—think of it as how much of a product would be toxic to half the users.
at-the-market offering
financial
“The filing also includes a prospectus supplement for an at-the-market offering of up to $100,000,000…”
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
AI-generated analysis. Not financial advice.
04/17/2026 – 02:00 PM
Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts.
Derived predominantly from turmeric (~98.5%), maintaining a composition closer to the natural profile of the plant.
Utilizes a turmeric-derived ingredient described as self-affirmed GRAS and evaluated in published research showing up to 39× higher free curcumin bioavailability under study conditions.
CHICAGO, IL / ACCESS Newswire / April 17, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the planned Q2 2026 U.S. market launch of Cur18, a next-generation curcumin supplement, marking a further step in the Company’s expansion into the U.S. nutraceutical market.
Cur18 enters the U.S. curcumin category as a science-driven alternative to conventional curcumin formulations, addressing one of the most fundamental limitations of the category: poor bioavailability. Based on published pharmacokinetic research, the formulation technology behind Cur18 has demonstrated significantly enhanced absorption, including up to 39× higher free curcumin bioavailability versus standard 95% curcuminoid extracts under study conditions.
The Bioavailability Problem with Conventional Curcumin
Curcumin is widely used for its antioxidant and anti-inflammatory properties, yet conventional curcumin formulations are known to have poor absorption. Because curcumin is hydrophobic, it does not dissolve efficiently in water-based environments and is often absorbed only to a limited extent in the digestive system. Curcumin’s poor aqueous solubility and low oral bioavailability are well established in the literature.
Cur18 is designed to address this challenge through an advanced formulation approach that enhances the dispersion and absorption of curcuminoids, supporting improved bioavailability and more efficient delivery. The underlying ingredient profile is described as retaining essential oils and polar resins alongside curcuminoids, unlike standard 95% curcuminoid extracts that lose much of this native turmeric matrix during processing.
39×
Higher free curcumin bioavailability than standard 95% curcuminoid extracts
49.5×
Higher total curcumin exposure (AUC) versus the C-95 reference in published pharmacokinetic research
~50%
North America share of global curcumin market revenue
Sources: Published pharmacokinetic study in Medicine (2021); Grand View Research; Mordor Intelligence
The Science Behind Cur18
Cur18 is based on a turmeric-derived, whole-spectrum extract designed to preserve key naturally occurring compounds found in turmeric, including curcuminoids, essential oils, and polar resins. The formulation is derived predominantly from turmeric (approximately 98.5%) and standardized to approximately 50% curcuminoids, maintaining a composition closer to the natural profile of the plant than conventional 95% curcuminoid extracts.
Unlike highly purified curcumin extracts that isolate specific compounds, this approach retains a broader matrix intended to support improved absorption and bioavailability through enhanced dispersion mechanisms.
Clinical & Scientific Evidence
Superior Bioavailability & Absorption:
A randomized, double-blind crossover pharmacokinetic study in 18 healthy adult male subjects reported up to 39× higher free curcumin bioavailability compared with standard 95% curcuminoids.
The same study reported 49.5× higher total curcumin AUC, along with a dual-phase absorption profile over 24 hours.
Joint Health Support
A randomized, double-blind, placebo-controlled osteoarthritis study in 101 subjects reported clinically meaningful improvements in knee pain and functional outcomes.
Regulatory & Safety Status
The ingredient has been described as self-affirmed GRAS (Generally Recognized as Safe) by an independent expert panel.
Additional data include LD50 > 5,000 mg/kg and a 90-day repeat-dose safety study supporting safety.
The formulation is ~98.5% turmeric-derived and developed without piperine or synthetic bio-enhancers.
Cur18 – Product Profile
Brand Name
Cur18
Active Ingredient
Turmeric-derived, clinically studied extract (500-1,000 mg per serving)
Source
~98.5% turmeric oleoresin (Curcuma longa) with advanced dispersion technology
Curcuminoid Content
~50% standardized curcuminoids
Bioavailability
Up to 39× higher vs standard extracts (published PK research)
Patent & GRAS
Patented formulation; self-affirmed GRAS ingredient
Functional Positioning
Joint health, antioxidant activity, gut health, mood, active lifestyle
Target Consumer
Adults 35+ • Joint health • Active aging • Post-workout recovery • Chronic inflammation support
Clinical Evidence
PK study (Medicine, 2021) + OA study (Nutrients, 2022)
Form
Capsules / Tablets
U.S. Market Opportunity – Multi-Billion Dollar Category
The U.S. turmeric supplement market is a well-established, consumer-driven category with broad demographic appeal. Curcumin’s antioxidant and anti-inflammatory properties support demand across a wide audience, including adults managing joint discomfort, athletes seeking recovery support, and consumers focused on preventive wellness.
The global turmeric market is valued at approximately $4.9 billion in 2025 and projected to reach $8.4 billion by 2035, reflecting sustained growth in nutraceutical demand (Source: Future Market Insights, 2025)
North America represents a key region, driven by strong adoption of preventive healthcare and dietary supplements. A major consumer trend is the shift toward high-bioavailability, evidence-based formulations.
While conventional curcumin products remain widely available, the premium, high-performance segment remains underpenetrated, creating a clear opportunity for differentiated formulations.
Why Cur18 Stands Apart
Enhanced Bioavailability: Cur18 is powered by a clinically studied, patented formulation demonstrating up to a 39× bioavailability advantage over standard 95% curcuminoids in published research.
Safety Profile: The formulation is based on an ingredient described as self-affirmed GRAS (Generally Recognized as Safe), supporting established safety standards for food and supplement use.
Clean-Label “Pure Turmeric” Profile: Unlike formulations that rely on synthetic bio-enhancers or black pepper extract (piperine), Cur18 is derived predominantly from turmeric (~98.5%), supporting a clean-label composition.
Pharmacokinetic Profile: Confirmed in a human PK study, Cur18 demonstrates a dual-peak 24-hour absorption profile, supporting sustained levels of curcuminoids over time.
Preserved Native Matrix: The formulation utilises a “whole-plant” approach, preserving a broad turmeric-derived matrix-including curcuminoids, essential oils, and polar resins.
Published Clinical Support: Supported by peer-reviewed clinical research, including a randomized controlled trial (RCT) demonstrating improvements in joint health and functional outcomes.
Multi-Functional Positioning: Applicable across multiple wellness areas, including joint health, inflammation support, gut health, mood, and exercise recovery.
U.S. Market Entry Strategy
Cur18 is planned to be made available through multiple channels targeting the U.S. nutraceutical market, including e-commerce platforms such as Amazon, direct-to-consumer channels, health and specialty retail locations, and healthcare practitioner networks.
Greg Siokas, CEO of Cosmos Health, stated: “Cur18 represents a new standard in curcumin supplementation. For decades, consumers have been told that turmeric is powerful – but conventional formulations have been limited by poor absorption. With Cur18, we are introducing a clinically studied, patented formulation designed to enhance bioavailability and deliver meaningful results. This launch reflects our broader strategy to expand in the U.S. market with differentiated, science-based nutraceutical products.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
What is Cosmos Health announcing about Cur18 (COSM) for Q2 2026?
Cosmos Health plans a U.S. launch of Cur18 in Q2 2026 as a multi-channel retail and DTC product. According to the company, Cur18 is a patented, turmeric‑derived supplement positioned for joint health with published PK and clinical studies supporting bioavailability and efficacy.
How much higher is Cur18 bioavailability compared with standard curcumin (COSM)?
Cur18 demonstrated up to 39× higher free curcumin bioavailability versus standard 95% extracts. According to the company, a published PK study also reported 49.5× higher total curcumin AUC versus the C-95 reference under study conditions.
What clinical evidence supports Cur18’s joint health claims for Cosmos Health (COSM)?
An RCT of 101 subjects reported clinically meaningful knee pain and functional improvements versus placebo. According to the company, this trial supports Cur18’s positioning for joint health alongside the PK study demonstrating enhanced absorption.
What is Cur18’s formulation and safety status as described by Cosmos Health (COSM)?
Cur18 is a ~98.5% turmeric‑derived, whole‑spectrum extract standardized to ~50% curcuminoids without piperine. According to the company, the ingredient is patented and described as self‑affirmed GRAS, with supportive safety studies including a 90‑day repeat‑dose study.
Where will Cosmos Health (COSM) sell Cur18 in the U.S. after the Q2 2026 launch?
Cosmos Health intends to distribute Cur18 through e-commerce (including Amazon), direct‑to‑consumer, health and specialty retail, and practitioner networks. According to the company, the multi‑channel approach targets adults 35+ focused on joint health and active aging.